The Development of ATM Inhibitors in Cancer Therapy

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The ataxia-telangiectasia mutated (ATM) protein kinase is crucial for DNA double-strand break repair and genomic stability.
• ATM mutations are common in cancers, creating vulnerabilities that can be exploited therapeutically.
• Small molecule inhibitors targeting ATM have emerged as a significant area of cancer drug development.

Purpose of the Study:

• To review the development and clinical application of ATM inhibitors in cancer therapy.
• To discuss the limitations of current ATM inhibitors and recent advancements.
• To explore the role of ATM inhibitors in personalized medicine and identify challenges for broader clinical adoption.

Main Methods:

• Literature review of preclinical and clinical studies on ATM inhibitors.
• Analysis of the mechanisms of action and therapeutic strategies involving ATM inhibition.
• Discussion of ongoing clinical trials and future research directions.

Main Results:

• ATM inhibitors demonstrate versatility in preclinical models and are increasingly used in clinical settings.
• Advances have led to a greater number and diversity of clinical trials targeting ATM.
• Understanding ATM's role is key to developing effective personalized cancer treatments.

Conclusions:

• ATM inhibitors represent a valuable therapeutic strategy for various cancers, particularly those with ATM deficiencies.
• Overcoming current limitations and addressing challenges in clinical application are essential for maximizing the benefit of ATM inhibitors.
• Further research into ATM's function and inhibitor development holds significant promise for personalized oncology.